169 related articles for article (PubMed ID: 36626706)
1. Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms.
Kitata RB; Hu LY; Lin TT; Nicora CD; Fillmore TL; Nie S; Hudson RD; Liu T; Leach RJ; Liu AY; Qian WJ; Shi T
J Proteome Res; 2023 Mar; 22(3):942-950. PubMed ID: 36626706
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of prostate specific antigen isoforms using immunoprecipitation and stable isotope labeling mass spectrometry.
Chen YT; Tuan LP; Chen HW; Wei IA; Chou MY; Chen HM; Tyan YC; Chen SF
Anal Chem; 2015 Jan; 87(1):545-53. PubMed ID: 25427836
[TBL] [Abstract][Full Text] [Related]
3. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
Mikolajczyk SD; Catalona WJ; Evans CL; Linton HJ; Millar LS; Marker KM; Katir D; Amirkhan A; Rittenhouse HG
Clin Chem; 2004 Jun; 50(6):1017-25. PubMed ID: 15054080
[TBL] [Abstract][Full Text] [Related]
4. PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.
Heidegger I; Klocker H; Pichler R; Horninger W; Bektic J
Anticancer Res; 2015 Jun; 35(6):3567-70. PubMed ID: 26026127
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
6. [[-2] proPSA: A Novel Marker of Prostate Cancer].
Ishikura K
Rinsho Byori; 2015 Jan; 63(1):84-93. PubMed ID: 26524883
[TBL] [Abstract][Full Text] [Related]
7. ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.
Heidegger I; Klocker H; Pichler R; Pircher A; Prokop W; Steiner E; Ladurner C; Comploj E; Lunacek A; Djordjevic D; Pycha A; Plas E; Horninger W; Bektic J
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):271-275. PubMed ID: 28322234
[TBL] [Abstract][Full Text] [Related]
8. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
[TBL] [Abstract][Full Text] [Related]
9. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.
Hori S; Blanchet JS; McLoughlin J
BJU Int; 2013 Oct; 112(6):717-28. PubMed ID: 22759214
[TBL] [Abstract][Full Text] [Related]
10. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Mikolajczyk SD; Rittenhouse HG
Keio J Med; 2003 Jun; 52(2):86-91. PubMed ID: 12862359
[TBL] [Abstract][Full Text] [Related]
11. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.
Abrate A; Lughezzani G; Gadda GM; Lista G; Kinzikeeva E; Fossati N; Larcher A; Dell'Oglio P; Mistretta F; Buffi N; Guazzoni G; Lazzeri M
Korean J Urol; 2014 Jul; 55(7):436-45. PubMed ID: 25045441
[TBL] [Abstract][Full Text] [Related]
15. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
Zhang MZ; Lu YP
Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836
[TBL] [Abstract][Full Text] [Related]
16. [Recent advances in proPSA on early detection in prostate cancer].
Zhu PY; Hong P; Huang YF
Zhonghua Nan Ke Xue; 2005 Dec; 11(12):944-6. PubMed ID: 16398372
[TBL] [Abstract][Full Text] [Related]
17. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
18. Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Stephan C; Meyer HA; Paul EM; Kristiansen G; Loening SA; Lein M; Jung K
Anticancer Res; 2007; 27(4A):1833-6. PubMed ID: 17649780
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
20. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
